ADVFN US – Market Content Editor

American Fusion says its Texatron program is targeting unity or beyond-unity testing by the end of 2026, while prospective commercial opportunities remain dependent on successful validation. Key Investor Takeaways Why AMFN Stock Is in Focus American Fusion provided additional details about its Texatron testing and commercialization strategy through an interview with Executive Chairman Brent Nelson.…

Black Dragon Resource says its chairman and CEO is committing funds without convertible notes or toxic investments as the company targets share retirement, an acquisition and an upgrade to a higher trading tier. Key Investor Takeaways Why BDGR Stock Is in Focus Black Dragon Resource announced a financial commitment from its chairman and CEO aimed…

The first overseas purchase of AeroVironment’s LOCUST laser weapon system expands the directed energy platform beyond its U.S. deployments and follows a $464.8 million U.S. Army contract. Key Investor Takeaways Why AVAV Stock Is in Focus AeroVironment has secured its first international LOCUST counter-drone system order, moving the high-energy laser platform into an overseas commercial…

The completed SKNJCT-003 study is shaping Medicus Pharma’s next clinical strategy, with the 200 µg dose moving into an FDA-authorized Gorlin syndrome program while the company considers partnerships for nodular basal cell carcinoma. Key Investor Takeaways Why MDCX Stock Is in Focus Medicus Pharma has published an abridged final Clinical Study Report for its Phase…

Fiscal 2026 revenue fell 10.8% to $1.50 billion and adjusted EBITDA declined to $2.9 million, while the company amended its credit agreement and began reviewing financing and asset-sale alternatives. Key Investor Takeaways Why FLWS Stock Is in Focus 1-800-FLOWERS.COM reported lower fiscal 2026 revenue and adjusted profitability while outlining measures intended to provide additional financial…

The FDA is expected to decide by January 10, 2027, after a Phase III study showed Enspryng reduced the risk of MOGAD relapse by 68% versus placebo. Key Investor Takeaways Why RHHBY Stock Is in Focus The FDA granted Priority Review to Genentech’s application seeking to expand Enspryng into myelin oligodendrocyte glycoprotein antibody-associated disease, or…

StrainScan Pro is being tailored for leafy greens, berries, tomatoes and tree fruit as Medical Care Technologies targets crop-specific visual quality inspection applications. Key Investor Takeaways Why MDCE Stock Is in Focus Medical Care Technologies is configuring StrainScan Pro AI vision modules around leafy greens, berries, tomatoes and tree fruit rather than relying on a…